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Abstract
Molecular interactions between killer immunoglobulin-like receptors (KIRs) and their MHC class I ligands play a central role
in the regulation of natural killer (NK) cell responses to viral pathogens and tumors. Here we identify Mamu-A1*00201
(Mamu-A*02), a common MHC class I molecule in the rhesus macaque with a canonical Bw6 motif, as a ligand for Mamu-
KIR3DL05. Mamu-A1*00201 tetramers folded with certain SIV peptides, but not others, directly stained primary NK cells and
Jurkat cells expressing multiple allotypes of Mamu-KIR3DL05. Differences in binding avidity were associated with
polymorphisms in the D0 and D1 domains of Mamu-KIR3DL05, whereas differences in peptide-selectivity mapped to the D1
domain. The reciprocal exchange of the third predicted MHC class I-contact loop of the D1 domain switched the specificity
of two Mamu-KIR3DL05 allotypes for different Mamu-A1*00201-peptide complexes. Consistent with the function of an
inhibitory KIR, incubation of lymphocytes from Mamu-KIR3DL05
+ macaques with target cells expressing Mamu-A1*00201
suppressed the degranulation of tetramer-positive NK cells. These observations reveal a previously unappreciated role for
D1 polymorphisms in determining the selectivity of KIRs for MHC class I-bound peptides, and identify the first functional
KIR-MHC class I interaction in the rhesus macaque. The modulation of KIR-MHC class I interactions by viral peptides has
important implications to pathogenesis, since it suggests that the immunodeficiency viruses, and potentially other types of
viruses and tumors, may acquire changes in epitopes that increase the affinity of certain MHC class I ligands for inhibitory
KIRs to prevent the activation of specific NK cell subsets.
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Introduction
Natural killer (NK) cells are able to lyse infected or malignant
cells without prior antigenic stimulation, and thus provide an
important innate defense against infectious agents and tumors
[1,2]. NK cell activation in primates is regulated in part through
interactions between the highly polymorphic killer immunoglob-
ulin-like receptors (KIRs) expressed on NK cells and their MHC
class I ligands on target cells [1,2]. KIRs are type I integral
membrane proteins with either two or three immunoglobulin (Ig)-
like extracellular domains (2D or 3D) that transduce either
inhibitory or activating signals via long (L) or short (S) cytoplasmic
domains, respectively. Engagement of inhibitory KIRs by MHC
class I molecules on healthy cells normally suppresses NK cell
activation [1,3,4]. However, if these interactions are perturbed, for
instance as a result of MHC class I downregulation by HIV-1 Nef
[5,6], or presentation of a peptide antagonist [7], this inhibition is
lost resulting in NK cell activation and target cell lysis.
In contrast to the T cell receptor, which is highly specific for a
given peptide-MHC complex, KIRs typically recognize subsets of
MHC class I molecules with common amino acid motifs in their
a1 domains. Based on serological epitopes that correspond to
defined sequences at positions 77-83, all HLA-B molecules, and
some HLA-A molecules, can be classified as either Bw4 or Bw6
allotypes [8]. Allotypes of KIR3DL1 have broad specificity for
HLA-Bw4 ligands [9], whereas KIRs specific for HLA-Bw6 have
not been identified. All inhibitory KIRs that have been examined
thus far also exhibit selectivity for peptides bound by their MHC
class I ligands [10,11,12,13,14,15,16]. These observations are
consistent with crystal structures of KIR2DL1 and KIR2DL2 in
complex with their HLA-C ligands showing that KIR residues
contact surfaces of the HLA class I a1 and a2 domains in an
orthogonal orientation across C-terminal residues of the bound
peptide [17,18]. However, the molecular basis for the selectivity of
KIRs for different peptides bound by a particular MHC class I
ligand has not been defined.
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KIR and HLA class I genes play an important role in determining
the course of infection for a number of human viral pathogens,
including HIV-1 [19,20], hepatitis C virus [21], human papillo-
mavirus [22] and cytomegalovirus [23]. In the case of HIV-1,
combinations of both activating and inhibitory KIR3DL1/S1 and
HLA-Bw4 alleles have been associated with delayed progression to
AIDS [19,20]. NK cells expressing KIR3DS1 were also shown to
suppress the in vitro replication of HIV-1 in target cells expressing
HLA-Bw4 [24]. While these observations point to a role for KIR-
MHC class I interactions in determining the outcome of HIV-1
infection, studies to address the functional significance of these
interactions have been limited, in part, by the lack of a suitable
animal model.
Simian immunodeficiency virus (SIV) infection of the rhesus
macaque is an important animal model for lentiviral pathogenesis
and for AIDS vaccine development [25]. Rhesus macaques
express MHC class I molecules that correspond to products of
the classical HLA-A and -B genes (Macaca mulatta; Mamu-A and -B),
but not the HLA-C gene [26,27]. Consistent with the co-evolution
of KIR and MHC class I molecules, genes for the two-domain
KIRs specific for HLA-C have not been identified in macaques
[28,29]. Instead, macaques have an expanded repertoire of
KIR3DL genes characterized by extensive polymorphism and gene
duplication [28,29,30,31,32].
Here we identify Mamu-A1*00201, a common rhesus macaque
MHC class I molecule with a Bw6 motif, as a ligand for multiple
allotypes of Mamu-KIR3DL05. We show that the binding of
Mamu-KIR3DL05 to Mamu-A1*00201 is peptide-dependent,
and that the relative avidity and peptide-selectivity of binding is
determined by polymorphisms in the D0 and D1 domains. We
also demonstrate that target cells expressing Mamu-A1*00201
suppress the degranulation of primary Mamu-KIR3DL05
+ NK
cells. These observations reveal a previously unappreciated role for
D1 polymorphisms in determining the selective recognition of
MHC class I-bound peptides by KIRs, and define the first
functional KIR-MHC class I interaction in the rhesus macaque.
Results
Peptide-dependent tetramer staining of primary rhesus
macaque NK cells
Samples of peripheral blood from Mamu-A1*00201
+ rhesus
macaques were stained with Mamu-A1*00201 tetramers folded
with SIV peptides to establish baseline CD8
+ T cell responses
prior to beginning a vaccine study. To our surprise, Mamu-
A1*00201 in complex with the Gag71-79 GY9 peptide stained a
subset of CD8
+CD3
– lymphocytes from one animal (Mm 337-07).
Plasma from this animal tested negative for SIV RNA and for
antibodies to viral antigens, indicating that this animal had not
been previously exposed to SIV. The majority of tetramer-
positive cells expressed CD8a and CD16, characteristic of NK
cells that are capable of mediating cytolytic activity [33], as well
as additional NK cell markers including NKp46, NKG2A, and
NKG2D (Fig. 1A). A subset of these cells also cross-reacted with
an antibody to human KIR2D (Fig. 1A). Although most of the
tetramer-positive cells were CD16
+CD3
– NK cells, staining was
also observed for CD8
+CD3
+ T cells (Fig. 1B). A longitudinal





– lymphocytes revealed that these two
populations were relatively stable in this animal over more than
a year, ranging from 0.16% to 0.69% for CD8
+ T cells and from
5.1% to 9.8% for CD16
+ NK cells. To investigate the
contribution of the peptide bound by Mamu-A1*00201 to
this unusual pattern of tetramer staining, whole blood was
stained with Mamu-A1*00201 tetramers folded with peptides
corresponding to eight different CD8
+ T cell epitopes of SIV
[34]. In addition to Gag71-79 GY9, staining was also observed for
Env788-795 RY8, but not for any of the other tetramers (Fig. 1C).
Thus, the tetramer staining observed for primary NK cells and
CD8
+ T cells from Mm 337-07 was dependent on the peptide
bound by Mamu-A1*00201.
Identification of Mamu-KIR3DL05 as a receptor for
Mamu-A1*00201
Since KIRs are known to be expressed on subsets of human NK
cells and CD8
+ T cells [4,35,36], we hypothesized that this pattern
of tetramer staining might reflect Mamu-A1*00201 binding to a
rhesus macaque KIR. Full-length KIR cDNA sequences were
therefore cloned from the PBMCs of Mm 337-07 and sequenced.
Six KIR3DL alleles, three KIR3DS alleles and two KIR2DL04 alleles
were identified in this animal, and their predicted amino acid
sequences are shown in Fig. 2.
To identify the receptor for Mamu-A1*00201, Jurkat cells were
transfected with constructs expressing each of the KIR alleles
cloned from Mm 337-07 and stained with Mamu-A1*00201
tetramers. To differentiate transfected from untransfected cells, the
KIR alleles were expressed from a bicistronic vector that co-
expresses enhanced green fluorescent protein (eGFP). Since not all
KIRs are well expressed on the cell surface, and antibodies are not
available to macaque KIRs, an HA tag was introduced at the
N-terminus of the D0 domain of each KIR. Our rationale for
introducing the HA tag at this position is based on a recent three-
dimensional model showing that the N-terminus of KIR3DL1 is
free and oriented away from surfaces that are predicted to con-
tact the peptide-MHC class I complex [37], and experiments
demonstrating that the introduction of an epitope tag at the
N-terminus of the D0 domain does not interfere with ligand
recognition [38]. Following the electroporation of Jurkat cells with
these KIR expression constructs, the cells were stained with
Mamu-A1*00201 tetramers and with a monoclonal antibody to
the HA tag. Transfected cells were identified by gating on the
Author Summary
NK cells provide an important first line of defense against
infectious diseases and tumors by virtue of their ability to
kill infected or malignant cells without prior sensitization.
NK cell activation is regulated in part through interactions
between KIRs expressed on the surface of NK cells and
their MHC class I ligands on target cells. Here we identify
Mamu-A1*00201 (Mamu-A*02), a common MHC class I
molecule in the rhesus macaque, as a ligand for Mamu-
KIR3DL05. We show that this interaction is peptide-
dependent, since soluble Mamu-A1*00201 tetramers
folded with certain SIV peptides, but not others, stained
cells expressing Mamu-KIR3DL05. Differences in binding
avidity were associated with polymorphisms in the D0 and
D1 domains of Mamu-KIR3DL05, whereas differences in
peptide-specificity mapped to the D1 domain. These
observations reveal a previously unappreciated role for
D1 polymorphisms in determining the selectivity of KIRs
for MHC class I-bound peptides, and identify the first
functional KIR-MHC class I interaction in the rhesus
macaque. These observations suggest that SIV, and
potentially also HIV-1, may acquire changes in epitopes
that increase the avidity of MHC class I ligands for
inhibitory KIRs as a mechanism of immune evasion to
prevent the activation of certain NK cell subsets.
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+ population, the surface expression of each KIR was verifi-
ed by HA staining, and binding to Mamu-A1*00201 in complex
with Gag71-79 GY9 versus Nef159-167 YY9 was assessed by tetramer
staining.
All of the KIRs were expressed on the cell surface under the
conditions of this assay, as indicated by HA staining (Fig. 3).
However, only Mamu-KIR3DL05*008 resulted in a detectable
level of staining with the Gag71-79 GY9 tetramer (Fig. 3A). At
higher levels of surface expression, staining was also observed for
Nef159-167 YY9, indicating that this tetramer can bind to Mamu-
KIR3DL05*008 under conditions of protein over expression
(Fig. 3A). These results identify Mamu-KIR3DL05*008 as a
receptor for Mamu-A1*00201, and indicate that the peptide
bound by Mamu-A1*00201 can modulate this interaction.
Polymorphic differences among allotypes of Mamu-
KIR3DL05 modulate the relative avidity and peptide-
selectivity of binding to Mamu-A1*00201
Phylogenetic comparisons of macaque KIR3DL sequences revealed
that Mamu-KIR3DL05*008 belongs to a group of similar alleles found
in both rhesus and cynomolgus macaques [29]. To determine if other
allotypes of Mamu-KIR3DL05 could also bind to Mamu-A1*00201,
Jurkat cells were transfected with constructs expressing six additional
Mamu-KIR3DL05 alleles, as well as six Mamu-KIR3DL07 alleles. The
transfected cells were then stained with Mamu-A1*00201 tetramers
folded with four different SIV peptides to assess binding; Gag71-79
GY9, Env788-795 RY8, Nef159-167 YY9 and Vif89-97 IW9.
One, or more, of the Mamu-A1*00201 tetramers bound to cells
expressing each of the Mamu-KIR3DL05 alleles. Cells express-
ing Mamu-KIR3DL05*004, -KIR3DL05*003, -KIR3DL05*010,
-KIR3DL05*008and -KIR3DL05*005stained with Gag71-79GY9,
Env788-795 RY8 and Nef159-167 YY9, whereas cells expressing
Mamu-KIR3DL05*001 and mmKIR3DL05x stained only with
Gag71-79 GY9or Nef159-167YY9(Fig. 4A). In contrast, none of these
KIRs bound to the Vif89-97 IW9 tetramer (Fig. 4A). Furthermore,
none of the Mamu-KIR3DL07 alleles resulted in a detectable level of
staining for any of the Mamu-A1*00201 tetramers (Fig. S1). Hence,
this interaction is dependent on the peptide bound by Mamu-
A1*00201 and is specific for Mamu-KIR3DL05.
Mamu-KIR3DL05*003, -KIR3DL05*008 and -KIR3DL05*010,
were indistinguishable in their pattern of tetramer staining (Fig. 4A).
This is reflected by the similarity in their values for the mean
fluorescence intensity (MFI) of tetramer staining divided by the MFI
of HA staining, which are provided in Table 1 as a quantitative
comparison of tetramer binding corrected for differences in surface
expression for each KIR. In accordance with the rank order of
tetramer staining observed for primary NK cells (Fig. 1C), staining
was highest for Gag71-79 GY9, followed by Env788-795 RY8, and then
Nef159-167 YY9 (Fig. 4A and Table 1). With the exception of a single
amino acid difference in the first position of the D0domainof Mamu-
KIR3DL05*010, each of these KIRs have identical Ig-like domains
(Fig. 4B).
Relative to Mamu-KIR3DL05*008, Mamu-KIR3DL05*004
exhibited an increase in the intensity of tetramer staining for
Gag71-79 GY9 (1.3 fold), Env788-795 RY8 (2.0 fold) and Nef159-167
YY9 (4.3 fold) (Fig. 4A and Table 1). Since the Ig-like domains of
Mamu-KIR3DL05*004 and Mamu-KIR3DL05*008 only differ
by a single amino acid at position 138 (Fig. 4B), the histidine
residue at this position accounts for the increase in Mamu-
KIR3DL05*004 binding to Mamu-A1*00201. Based on a recently
proposed three-dimensional model of KIR3DL1*015 bound to
HLA-A*2402 [37], this residue is predicted to lie at the base of the
second MHC class I-contact loop of the D1 domain, and may alter
the conformation of this loop in a way that enhances binding to
Mamu-A1*00201.
Compared to Mamu-KIR3DL05*008, decreases in the inten-
sity of tetramer staining were observed for both Mamu-
KIR3DL05*005 and -KIR3DL05*001 (Fig. 4A). The intensity
of staining for Mamu-KIR3DL05*005, which differs from
Mamu-KIR3DL05*008 by 14 amino acids (Fig. 4B), was 2.7-
fold lower for Gag71-79 GY9, 2.3-fold lower for Env788-795 RY8
and 3.0-fold lower for Nef159-167 YY9 (Table 1). A much greater
reduction in the intensity of tetramer staining was observed
for Mamu-KIR3DL05*001. Tetramer staining for Mamu-
KIR3DL05*001 was only detectable with Gag71-79 GY9 at an
intensity that was 75-fold lower than for Mamu-KIR3DL05*008
(Table 1). Since Mamu-KIR3DL05*001 and -KIR3DL05*008
differ by ten amino acids in D0, but are otherwise identical in D1
and D2 (Fig. 4B), this reduction in the avidity of binding to
Figure 1. Peptide-dependent tetramer staining of primary NK
cells and CD8
+ T cells from an unimmunized, uninfected rhesus
macaque. (A) To identify the tetramer-positive cells, whole blood was
stained with Mamu-A1*00201 Gag71-79 GY9 followed by monoclonal
antibodies to the indicated cell type-specific markers. (B) The frequency
of tetramer-positive CD8
+ T cells versus CD16
+ NK cells was determined
by gating sequentially on CD8 followed by CD3 (I) or CD16 (II). (C) To
determine if tetramer staining is dependent on the peptide bound by
Mamu-A1*00201, whole blood was stained with Mamu-A1*00201
tetramers folded with eight different SIV peptides, Gag71-79 GY9
(GSENLKSLY), Env788-795 RY8 (RTLLSRVY), Env317-325 KM9 (KTVLPVTIM),
Nef248-256 LM9 (LTARGLLNM), Nef159-167 YY9 (YTSGPGIRY), Env296-304 RY9
(RTIISLNKY), Vif97-104 WY8 (WTDVTPNY), and Vif89-97 IW9 (ITWYSKNFW),
followed by monoclonal antibodies to CD3, CD8 and CD16. After gating
on CD8
+ lymphocytes, the percentages of tetramer-positive CD3
–
versus CD3
+ cells were determined.
doi:10.1371/journal.ppat.1001316.g001
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PLoS Pathogens | www.plospathogens.org 3 March 2011 | Volume 7 | Issue 3 | e1001316Figure 2. Amino acid sequence alignments for KIR alleles cloned from a rhesus macaque with a tetramer-positive NK cell
population in peripheral blood. The predicted amino acid sequences are shown for six Mamu-KIR3DL alleles (A), three Mamu-KIR3DS alleles (B),
and two Mamu-KIR2DL04 alleles (C). Positions of amino acid identity with the consensus sequence shown at the top are indicated by a period and
translational stop sites are indicated with an asterisk.
doi:10.1371/journal.ppat.1001316.g002
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domain. Thus, similar to KIR3DL1-HLA-Bw4 interactions in
humans [37,39], polymorphisms in the D0 domain of Mamu-
KIR3DL05 can dramatically affect binding to MHC class I
ligands.
In the case of mmKIR3DL05x, tetramer staining was observed
for Nef159-167 YY9, but not for Gag71-79 GY9 or Env788-795 RY8
(Fig. 4A). This shift in the pattern of Mamu-A1*00201 tetramer
staining almost certainly reflects differences in D1, since
mmKIR3DL05x has a unique D1 domain, but nearly identical
D0 and D2 domains to other allotypes of Mamu-KIR3DL05
(Fig. 4B). Using cryopreserved PBMCs from the original source of
mmKIR3DL05x, we verified that mmKIR3DL05x represents a bona
fide allele, and not a PCR artifact, by independently cloning and
confirming the cDNA sequence for this allele, and by PCR
amplification of a 2.0 kb region spanning intron 4 from genomic
DNA with primers to unique sequences in exons 4 and 5.
Additional sequence comparisons revealed that the D1 domain of
mmKIR3DL05x, as well as the leader peptide and the D0 domain,
are identical to Mamu-KIR3DS02*00402 and mmKIR3DHa
(Fig. S2). Thus, mmKIR3DL05x appears to be the product of a
recombination event in which exon 4 (encoding D1) was acquired,
either by the introduction of exons 1-4 of a Mamu-KIR3DS gene
into -KIR3DL05 or by the introduction of exons 5-9 of Mamu-
KIR3DL05 into a -KIR3DS gene.
A closer examination of mmKIR3DL05x revealed that seven of
the thirteen differences in the D1 domain coincide with, or are
immediately adjacent to, loops predicted to contact surfaces of the
peptide-MHC class I complex [37]. These include a charge
difference at position 144 in the second loop (L2) and a cluster of
six residues at positions 164–170 in the third loop (L3) (Fig. 4B and
Fig. 5A). To determine if these differences account for the unique
binding pattern exhibited by mmKIR3DL05x, we constructed
recombinants in which these sequences were exchanged with the
corresponding sequences of Mamu-KIR3DL05*008, and tested
them for binding to Gag71-79 GY9 versus Nef159-167 YY9.
Reciprocal L2 substitutions affected the avidity, but not the
specificity, of tetramer binding (Fig. 5B). In contrast, exchanging
L3 residues switched the specificity, and altered the avidity, of
binding to the Mamu-A1*00201 tetramers. The 3DL05*008/xL3
recombinant bound Nef159-167 YY9, but not Gag71-79 GY9, and
the 3DL05x/*008L3 recombinant bound both Gag71-79 GY9 and
Nef159-167 YY9 (Fig. 5B). Hence, these results reveal a role for
polymorphisms in the third predicted contact loop of the D1
domain in determining the selective recognition of different
peptides bound by the same MHC class I molecule.
Figure 3. Mamu-A1*00201 is a ligand for Mamu-KIR3DL05. Jurkat cells were transfected with constructs expressing each of the six Mamu-
KIR3DL (A), three Mamu-KIR3DS (B), and two Mamu-KIR2DL04 (C) alleles cloned from Mm 337-07, and stained with Gag71-79 GY9 and Nef159-167 YY9
tetramers. The KIRs were expressed from a bicistronic vector designed to introduce a common leader peptide followed by an HA tag at the N-
terminus of the D0 domain, and to co-express eGFP from a downstream internal ribosomal entry site. Jurkat cells were electroporated with the KIR
expression constructs and stained the following day with APC-conjugated Mamu-A1*00201 tetramers, followed by a PE-conjugated antibody to the
HA tag. Tetramer versus HA staining was determined after gating on the eGFP
+ cell population. Quadrant gates were set using empty vector-
transfected controls stained with tetramer and antibody to the HA tag.
doi:10.1371/journal.ppat.1001316.g003
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PLoS Pathogens | www.plospathogens.org 5 March 2011 | Volume 7 | Issue 3 | e1001316Figure 4. Polymorphisms in the D0 and D1 domains of Mamu-KIR3DL05 modulate the avidity and peptide-selectivity of binding to
Mamu-A1*00201. (A) Jurkat cells were transfected with HA-tagged Mamu-KIR3DL05 expression constructs, and stained the next day with APC-
conjugated Mamu-A1*00201 tetramers (Gag71-79 GY9, Env788-795 RY8, Nef159-167 YY9 or Vif89-97 IW9), followed by a PE-conjugated antibody to the HA
tag. Quadrant gates were set using empty vector-transfected controls stained with tetramer and antibody to the HA tag. (B) An alignment comparing
the predicted amino acid sequences of the D0, D1 and D2 domains for seven different Mamu-KIR3DL05 alleles. Positions of amino acid identity with
the consensus sequence are indicated by a period. The shaded regions correspond to loops predicted to contact surfaces of the peptide-MHC class I
complex [37]. The plus signs beneath the alignment indicate unique residues in the D1 domain of mmKIR3DL05x that coincide with, or are
immediately adjacent to, predicted MHC class I-contact loops.
doi:10.1371/journal.ppat.1001316.g004
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positive NK cells from Mamu-KIR3DL05
+ macaques
Additional Mamu-KIR3DL05
+ rhesus macaques were identified
by sequence-specific PCR and screened for tetramer-positive NK
cells and CD8





+ lymphocytes in in peri-
pheral blood from each of the Mamu-KIR3DL05
+ animals, but not
from Mamu-KIR3DL05
- animals (Fig. 6A and 6B). In accordance
with the complex regulation of KIR expression, which is
influenced by a number of factors including differences in gene
content on different KIR haplotypes, differences in the repertoire
of MHC class I genes and polymorphic differences in KIR genes
[40,41,42,43], there was considerable animal-to-animal variation
in the frequency and intensity of tetramer staining (Fig. 6B).
Variation in the frequency of tetramer-positive CD8
+CD3
+
lymphocytes, particularly in Mamu-A1*00201
2 animals that do
not have Gag71-79-specific CD8
+ T cells, may also reflect changes
in KIR expression on memory CD8
+ T cells related to age and/or
prior exposure to infectious agents, since similar changes have
been associated with age and encounters with viral pathogens in
humans [36,44,45]. Overall, these results demonstrate that the
presence of the Mamu-KIR3DL05 gene is predictive of Gag71-79
GY9 staining in peripheral blood, that this pattern of tetramer
staining is independent of Mamu-A1*00201 and SIV infection, and
that the variability of staining is typical of the heterogeneity of KIR
expression on human NK cells and CD8
+ T cells [36,46].
The role of NK cells and CD8
+ T cells that express Mamu-
KIR3DL05 in SIV-infected animals remains to be determined.
However, among the eight animals represented in Fig. 6B, there
were no obvious differences in the percentage of tetramer-positive
cells for either population that could be attributed to the status of
SIV infection. Indeed, of the two uninfected animals (Mm 177-05
and Mm RHAX18), the two animals infected with attenuated
SIVmac239 Dnef (Mm 350-04 and Mm 376-04), and the two
animals infected with pathogenic SIVmac239 (Mm R03035 and
Mm 20-05), each pair had among the lowest and the highest
frequencies of tetramer-positive lymphocytes (Fig. 6B). Some of the
tetramer-positive CD8
+CD3
+ lymphocytes in the Mamu-
A1*00201
+ animals probably represent virus-specific CD8
+ T
cells, since we cannot differentiate binding of the Gag71-79 GY9
tetramer to Mamu-KIR3DL05 versus the T cell receptor.
Nevertheless, in two of the three SIV-infected animals (Mm 350-
04 and Mm R02020), the percentage of tetramer-positive cells was
actually higher for the CD8
+CD3
2 population than for the
CD8
+CD3
+ population (Fig. 6B). Although the explanation for this
is presently unclear, it is possible that Mamu-KIR3DL05
interactions with Mamu-A1*00201 may suppress CD8
+ T cell
responses to the Gag71-79 GY9 epitope in Mamu-KIR3DL05
+
animals, which could explain the inconsistent, and often weak,
CD8
+ T cell responses to Gag71-79 GY9 that we and others have
observed in SIV-infected, Mamu-A1*00201
+ macaques.
To investigate the functional consequences of NK cell
recognition of Mamu-A1*00201, PBMC from four Mamu-
KIR3DL05
+ animals were stimulated with the MHC class I-
deficient 721.221 cell line [47], or with 721.221 cells expressing
either Mamu-A1*00201, -A1*01101 (Mamu-A*11) or -B*010101
(Mamu-B*01), and stained for CD107a as a degranulation marker.
The cells were also stained with Gag71-79 GY9 to differentiate
Mamu-KIR3DL05
+ NK cells from Mamu-KIR3DL05
2 NK cells.
CD107a was upregulated on the surface of both tetramer-positive
and tetramer-negative NK cells in response to parental 721.221
cells and 721.221 cells expressing Mamu-A1*01101 or -B*010101
(Fig. 6C). In contrast, CD107a was suppressed on tetramer-
positive NK cells, but not on tetramer-negative NK cells, in the
presence of target cells expressing Mamu-A1*00201 (Fig. 6C). The
same pattern of NK cell activation/inhibition was also observed by
intracellular cytokine staining for IFNc (Fig. S3). Moreover,
CD107a was suppressed on tetramer-positive NK cells from both
Mamu-A1*00201
+ and -A1*00201
2 animals (Fig. 6C), indicating
that these cells were responsive to Mamu-A1*00201 whether or
not they were educated in the presence of this MHC class I
molecule. These results are therefore consistent with the functional
inhibition of Mamu-KIR3DL05
+ NK cells by Mamu-A1*00201.
Discussion
Polymorphic differences in the KIR and HLA class I genes play
an important role in determining the course of infection for HIV-1
and for a number of other viral pathogens [19,20,21,22,23,24].
However, studies to address the functional significance of KIR-
MHC class I interactions have been hampered by the lack of a
suitable animal model. In the present study, we identify Mamu-
A1*00201, an MHC class I molecule present in approximately
20% of Indian origin rhesus macaques [48], as a ligand for
multiple allotypes of Mamu-KIR3DL05. Although the frequency
Table 1. Relative binding of Mamu-A1*00201 tetramers folded with four different SIV peptides to seven allotypes of Mamu-
KIR3DL05.
Mamu-A1*00201 tetramer
Mamu-KIR3DL05 Gag71-79 GY9 Env788-795 RY8 Nef159-167 YY9 Vif89-97 IW9
Mamu-KIR3DL05*004 1.99 0.14 0.13 —
Mamu-KIR3DL05*003 1.57 0.06 0.03 —
Mamu-KIR3DL05*010 1.55 0.07 0.03 —
Mamu-KIR3DL05*008 1.49 0.07 0.03 —
Mamu-KIR3DL05*005 0.55 0.03 0.01 —
Mamu-KIR3DL05*001 0.02 — — —
mmKIR3DL05x — — 0.10 —
Jurkat cells were transfected with constructs expressing HA-tagged allotypes of Mamu-KIR3DL05 and stained the next day with one of the following Mamu-A1*00201
tetramers; Gag71-79 GY9, Env788-795 RY8, Nef159-167 YY9 or Vif89-97 IW9. The cells were then stained with a monoclonal antibody to the HA tag and analyzed by flow
cytometry. Values represent the MFI of tetramer staining divided by the MFI of HA staining for the transfected, eGFP
+ cell population. Values were not calculated if the
number of tetramer-positive events was less than 1000.
doi:10.1371/journal.ppat.1001316.t001
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the Mamu-KIR3DL05 gene was present in 42% of the rhesus
macaques (43 of 103 animals) recently screened at the New
England Primate Research Center by sequence-specific PCR. This
suggests that animals expressing both Mamu-KIR3DL05 and
-A1*00201 are sufficiently common for use in future studies to
investigate the functional implications of this interaction with
respect to the pathogenesis of SIV infection.
Genotyping for Mamu-KIR3DL05 was predictive of Mamu-
A1*00201 tetramer staining for primary NK cells and CD8
+ T





+ lymphocytes from Mamu-
KIR3DL05
+ animals, but not from Mamu-KIR3DL05
2 animals, is
consistent with the variegated expression of KIRs on human NK
cells and CD8
+ T cells [4,35,36,49,50,51]. Tetramer staining was
independent of Mamu-A1*00201, reflecting the segregation of KIR
and MHC class I genes on different chromosomes, and was
detectable regardless of the status of SIV infection. Moreover, the
variability in the frequency and intensity of tetramer staining
among Mamu-KIR3DL05
+ animals was typical of the heterogeneity
of KIR expression on human NK cells and CD8
+ T cells [36,46].
Although tetramer staining has been reported for NK cell clones
and for transfected cells expressing human KIRs [11,12], to our
knowledge this is the first report of direct ex vivo tetramer staining
of primary NK cells.
Incubation of peripheral blood lymphocytes from Mamu-
KIR3DL05
+ macaques with target cells expressing Mamu-
A1*00201 specifically suppressed the degranulation of tetramer-
positive NK cells. These results are consistent with the functional
inhibition of primary NK cells expressing Mamu-KIR3DL05 by
Figure 5. Amino acid differences in the third MHC class I-contact loop of the D1 domain account for the preferential binding of
mmKIR3DL05x to the Nef159-167 YY9 tetramer. (A) Positions in the D1 domain of mmKIR3DL05x that differ from Mamu-KIR3DL05*008 are
highlighted in a three-dimensional model of KIR3DL*015 bound to HLA-A*2402 [37]. The residues indicated in yellow are located in surface-exposed
loops in close proximity to the bound peptide. The residues indicated in red represent differences in the D1 domain at sites that do not contribute
directly to interactions with MHC class I ligands. The residues highlighted in magenta represent positions 77-83 of the a1 domain corresponding to
the Bw6 of Mamu-A1*00201. (B) Jurkat cells were electroporated with constructs expressing recombinants of Mamu-KIR3DL05*008 and
mmKIR3DL05x, for which residues of the second (L2) and third (L3) predicted MHC class I-contact loops in D1 were exchanged, and stained with APC-
conjugated tetramer (Gag71-79 GY9 or Nef159-167 YY9) followed by a PE-conjugated antibody to the HA tag. Tetramer versus HA staining was
determined after gating on the eGFP
+ cell population and quadrant gates were set using control cells transfected with an empty vector.
doi:10.1371/journal.ppat.1001316.g005
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tetramer-positive NK cells from Mamu-A1*00201
2 as well as from
Mamu-A1*00201
+animals, indicating that these cells were respon-
sive to Mamu-A1*00201, whether or not they were educated in
animals that express this ligand. Although the mechanisms of NK
cell education are not fully understood [52], there is evidence that
the maturation of NK cells expressing inhibitory KIRs is
dependent on interactions with self-MHC class I molecules, and
that NK cells expressing a particular inhibitory KIR in the
absence of an appropriate MHC class I ligand are rendered
hyporesponsive [3,53,54]. Thus, the in vitro suppression of
tetramer-positive NK cells from Mamu-A1*00201
2 animals by
target cells expressing Mamu-A1*00201 implies that these cells
were educated for recognition of another MHC class I ligand. This
is perhaps not surprising given the complexity of the rhesus
macaque MHC class I genes [55,56], and the ability of KIRs to
recognize multiple MHC class I ligands with common amino acid
motifs in their a1 domains [9,57].
Based on haplotype modeling and phylogenetic comparisons,
Mamu-KIR3DL05 is predicted to represent a single genetic locus
[29]. Although KIR3DL05 is not orthologous to any of the
human KIR genes, interactions between Mamu-KIR3DL05 and
Mamu-A1*00201 resemble features of KIR3DL1 binding to
HLA-Bw4. A three-dimensional model of KIR3DL1*015 bound
to HLA-A*2402 was recently constructed based on a crystal
structure of KIR2DL1 in complex with HLA-C*04 [17,37]. This
model predicts that surface-exposed loops in each of the three
Ig-like domains of KIR3DL1 contact the HLA class I molecule
over the C-terminus of the bound peptide, and that the specificity
of KIR3DL1 for HLA-Bw4 is dependent on a salt bridge between
glutamate 282 in the D2 domain of KIR3DL1 and arginine 83 in
the a1 domain of HLA-Bw4 [37]. Consistent with this model,
polymorphisms in the Ig-like domains of Mamu-KIR3DL05 were
associated with differences in binding to Mamu-A1*00201.
Amino acid differences in D0 affected the relative avidity of
Mamu-KIR3DL05 binding to Mamu-A1*00201. Compared to
Mamu-KIR3DL05*003/*008, tetramer staining was diminished
for both Mamu-KIR3DL05*001 and -KIR3DL05*005, which
differ by eight and ten residues in D0 respectively. In the case of
Mamu-KIR3DL05*001, which is otherwise identical to Mamu-
KIR3DL05*003/*008 in D1 and D2, binding to Mamu-
A1*00201 was all but eliminated. These results are analogous to
previous observations showing that polymorphisms in the D0
domain of KIR3DL1 modulate the avidity of binding to HLA-
Bw4 ligands [37,39].
Polymorphisms in D1 altered the selective binding of Mamu-
KIR3DL05 to Mamu-A1*00201 in complex with different SIV
peptides. In contrast to other allotypes of Mamu-KIR3DL05,
Figure 6. Mamu-A1*00201
+ target cells suppress the degranulation of tetramer-positive NK cells. (A) Primers specific for exon 5 of
Mamu-KIR3DL05 were used to amplify a 156 bp sequence from genomic DNA. Primers specific for a conserved 300 bp region of Mamu-DRB were
included as an internal control. PCR products were separated on a 1% agarose gel containing ethidium bromide and visualized by UV
transillumination. (B) Peripheral blood from two Mamu-KIR3DL05
2 and eight Mamu-KIR3DL05
+ rhesus macaques was stained with the Gag71-79 GY9





lymphocytes. Of the eight Mamu-KIR3DL05
+ animals, four were Mamu-A1*00201
+ (Mm 177-05, Mm 350-04, Mm R02020 and Mm R95117) and four
were Mamu-A1*00201
- (Mm 20-05, Mm 376-04, Mm RHAX18 and Mm R03035). With the exception of Mm AP78 and Mm AD73INF08, which were
negative for Mamu-KIR3DL05, tetramer-positive NK cells were detected in peripheral blood for each of these animals. Mm AP78, Mm AD73INF08, Mm
177-05, and Mm RHAX18 were uninfected at the time of this analysis. Mm R02020 and Mm R95117 were infected with SIVsmmE660. Mm 350-04 and
376-04 were infected with SIVmac239Dnef. Mm 20-05 and Mm R03035 were infected with SIVmac239. The SIV-infected animals are indicated with an
asterisk. (C) Freshly isolated PBMC from two Mamu-A1*00201
+ and two Mamu-A1*00201
- macaques were stimulated with parental 721.221 cells, or
721.221 cells expressing individual rhesus macaque MHC class I molecules. Mm 337-07 was uninfected at the time of this analysis. The cells were
incubated overnight at a 5:1 PBMC to target cell ratio in the presence of a monoclonal antibody to CD107a. Following stimulation, the cells were
stained with the Gag71-79 GY9 tetramer and antibodies to CD3, CD8, CD16 and NKG2A. After gating on CD3
-NK2GA
+ lymphocytes, the upregulation of
CD107a on tetramer-positive versus tetramer-negative NK cells was determined.
doi:10.1371/journal.ppat.1001316.g006
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with Nef159-167 YY9 rather than Gag71-79 GY9. This difference in
peptide preference mapped to six amino acids in the third D1 loop
predicted to contact surfaces of the peptide-MHC class I complex.
These results support a recent three-dimensional model of
KIR3DL1*015 bound to HLA-A*2402 [37], and reveal a role
for polymorphisms in the D1 domain in determining the selectivity
of KIRs for MHC class I-bound peptides. Interestingly,
mmKIR3DL05x appears to be the product of a recombination
event in which exon 4 sequences coding for the D1 domain were
derived from a KIR3DS gene; an observation that is consistent with
domain shuffling as a mechanism of KIR evolution in primates
[58].
Unlike previously identified ligands for human KIRs, the a1
domain of Mamu-A1*00201 contains a Bw6 motif. In contrast to
Bw4, the Bw6 motif has a glycine rather than an arginine at
position 83 (N77LRNLRG83). Yet, Mamu-KIR3DL05 retains a
glutamate at position 285, which corresponds to glutamate 282 of
KIR3DL1. Since the peptides recognized by Mamu-KIR3DL05
each contain a positively charged residue at position 6 or 8
(Gag71-79 GSENLKSLY, Env788-795 RTLLSRVY and Nef159-167
YTSGPGIRY), it is conceivable that glutamate 285 may form an
alternative salt bridge with the peptide that accounts for the
peptide-dependence of Mamu-KIR3DL05. However, a charge at
this position does not appear to be sufficient for binding, since the
Vif89-97 IW9 peptide, which also contains a lysine at position 6
(ITWYSKNFW), did not result in detectable Mamu-A1*00201
tetramer staining. While the molecular interactions underlying the
binding of Mamu-KIR3DL05 to Mamu-A1*00201 remain to be
fully defined, these observations offer a potential explanation for
the contribution of the peptide to this interaction, and perhaps
suggest a more prominent role for certain peptides in KIR
recognition of other Bw6 ligands.
The extent to which KIR recognition of Bw6 ligands has been
elaborated in the rhesus macaque is presently unclear. However,
since this motif is retained in the MHC class I molecules of
humans and macaques, the absence of human KIRs that
recognize HLA-Bw6 appears to reflect the loss of receptors of
this specificity during the course of human evolutionary history.
While the reason for this is not understood, it may be related to the
expansion of the lineage III KIR genes coding for KIR2DL/S
receptors with a D1-D2 configuration, and a greater dependence
on the regulation of NK cell activation through interactions with
their HLA-C ligands.
The identification of inhibitory KIRs that bind with high
avidity to a common MHC class I molecule in the rhesus
macaque in complex with SIV-derived peptides suggests a
potential mechanism of immune evasion. The Nef proteins of
HIV-1 and SIV selectively downregulate MHC class I molecules
from the surface of infected cells to evade destruction by virus-
specific CD8
+ T cells [6,59]. However, the removal of these
molecules from the cell surface increases the susceptibility of
infected cells to elimination by NK cells [6]. By acquiring changes
in CD8
+ T cell epitopes that increase the binding of MHC class I
ligands to inhibitory KIRs, the virus may prevent the activation
of NK cells under conditions of incomplete downregulation by
Nef. This possibility is supported by recent evidence that peptides
can modulate NK cell activation by varying the affinity of HLA
ligands for inhibitory KIRs [7]. Whereas Fadda et al. show that
antagonistic peptides that disrupt MHC class I interactions with
inhibitory KIRs leads to NK cell activation [7], our data suggests
that viruses may acquire changes in epitopes that stabilize these
interactions to suppress NK cell activation in a way that favors
virus replication.
KIRs are also expressed on subsets of memory CD8
+ T cells in
HIV-1 infected individuals, and have been associated with a
decrease in the responsiveness to TCR-dependent stimulation
[44,60]. Thus, peptides that stabilize interactions with inhibitory
KIRs may also suppress CD8
+ T cell activation. Deleterious
combinations of KIR and MHC class I alleles may therefore select
for changes in epitopes of HIV-1 and SIV that inhibit certain NK
cell and CD8
+ T cell responses; a scenario that may further
undermine the host’s ability to contain virus replication. Consis-
tent with this hypothesis, a single nucleotide polymorphism was
recently identified as a marker for two Mamu-KIR3DL05 alleles
that were more prevalent among SIV-infected rhesus macaques
with high viral loads in animals [61].
The identification of Mamu-A1*00201 as a ligand for Mamu-
KIR3DL05 now affords an opportunity to investigate the
functional implications of KIR-MHC class I interactions. Using
KIR- and MHC class I-defined animals, experiments can now be
designed to examine the phenotypic changes that occur in a
specific population of NK cells during the course of virus infection
in a way the was previously only possible for CD8
+ T cells.
Characterization of the molecular interactions underlying the
binding of Mamu-KIR3DL05 to Mamu-A1*00201 also promises
to yield fundamental insights regarding the role of viral peptides in
modulating KIR recognition of MHC class I ligands. The binding
of Mamu-KIR3DL05 to Mamu-A1*00201 in complex with SIV
peptides suggests that these interactions may be particularly
important in determining the course of SIV infection.
Materials and Methods
Ethics statement
All of the animals used for these studies were Indian origin
rhesus macaques (Macaca mulatta). These animals were housed at
the New England Primate Research Center (NEPRC) and were
maintained in accordance with standards of the Association for
Assessment and Accreditation of Laboratory Animal Care and the
Harvard Medical School Animal Care and Use Committee.
Animal experiments were approved by the Harvard Medical Area
Standing Committee on Animals and conducted according to the
principles described in the Guide for the Care and Use of Laboratory
Animals [62].
KIR nomenclature and Genbank accession numbers
Rhesus macaque KIR sequences were submitted to Genbank
and to the Immuno-Polymorphism Database (www.ebi.ac.uk/ipd/
kir/) [63]. Sequences that have been assigned official names are
indicated with the prefix Mamu-KIR. In cases where official names
have not yet been assigned, sequences are referred to using a
provisional nomenclature indicated by the prefix mmKIR. The
names and Genbank accession numbers for each of the KIR alleles
in this study are listed in Table S1.
Phenotypic analysis of tetramer-positive lymphocytes
Whole blood was stained with Mamu-A1*00201 tetramers
folded with the SIV peptides Gag71-79 GY9, Env788-795 RY8,
Env317-325 KM9, Nef248-256 LM9, Nef159-167 YY9, Env296-304
RY9, Vif97-104 WY8, or Vif89-97 IW9 (30 min, 37uC) followed by
antibodies to cell type-specific markers (30 min, 20uC). Mamu-
A1*00201 tetramers were obtained from David Watkins’ labora-
tory (Wisconsin National Primate Research Center), and the
quality of each tetramer lot was verified by staining CD8
+ T
lymphocytes from SIV-infected rhesus macaques. For polychro-
matic assays, samples were stained with anti-CD3-Pacific blue
(SP34-2, BD Pharmingen), anti-CD4-AmCyan (L200, BD Phar-
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DR-PE Texas Red (Immu-257, Immunotech), anti-CD20 PE-
Cy5.5 (L27, BD Pharmingen), anti-CD56 PE-Cy7 (NCAM16.2,
BD Pharmingen), anti-CD8a-Alexa 700 (RPA-T8, BD Pharmin-
gen), anti-CD14-APC-Cy7 (MphiP9, BD Pharmingen), and either
anti-NKG2A-PE (Z1999, Beckman Coulter), anti-NKp46-PE
(BAB21, Immunotech), anti-KIR2D-PE (NKVFS1, Miltenyi
Biotec Inc.), or anti-NKG2D-PE (BAT221, Miltenyi Biotec Inc.)
For four-color assays, samples were stained with anti-CD3-FITC
(SP34-2, BD Pharmingen), anti-CD16-PE (3G8, BD Pharmingen),
and anti-CD8a-PerCP (SK1, BD Pharmingen). Samples were
treated with FACS Lysing solution (BD Biosciences) to eliminate
red blood cells, washed and fixed in 2% paraformaldehyde PBS.
Data was acquired using a LSRII flow cytometer (BD Biosciences)
and analyzed using FlowJo 8.8.6 (Tree Star Inc.).
Cloning and sequencing of rhesus macaque KIR alleles
Peripheral blood lymphocytes were isolated over Ficoll (Sigma)
and aliquots of 2–10 million PBMC were frozen in Trizol
(Invitrogen). Total RNA was extracted using the RNeasy kit
(Qiagen) according to the manufacturer’s instructions. KIR
cDNAs were amplified by reverse transcription-polymerase chain
reaction (RT-PCR) using the Superscript III One-Step RT-PCR
kit (Invitrogen) with modified versions of the Ig3Up and Ig3Down
primers [64]. Cycling conditions included an RT step at 55uC for
30 min, a denaturation step at 94uC for 2 min, followed by 40
cycles of denaturation (94uC for 15 sec), annealing (55uC for
30 sec) and extension (68uC for 90 sec), and a final extension step
at 68uC for 5 min. PCR products were cloned into the pGEM-T
Easy vector (Promega) and sequenced with T7 and SP6
sequencing primers. Sequences were analyzed using Sequencher
4.8 (Gene Codes Inc.) and MacVector 9.5.2 (MacVector Inc.)
software packages. At least three identical cDNA clones were
identified for each KIR allele.
KIR expression and tetramer staining of transfected
Jurkat cells
Rhesus macaque KIRs were PCR amplified from cDNA clones
using primers to introduce an HA tag at the N-terminus of the D0
domain. The KIR cDNAs were then cloned into pCGCG, a
bicistronic vector that co-expresses eGFP, in frame with an
upstream sequence for the leader peptide of Mamu-
KIR3DL05*008. Jurkat cells (1610
7 cells) were electroporated
(250V, 975mF) with plasmid DNA (40 mg) in serum-free RPMI
(400 ml) in a 0.4 cm cuvette (BioRad). After resting (10 min, 20uC),
the cells were re-suspended in RPMI medium (9 ml) with 10%
FBS and incubated overnight at 37uC, 5% CO2. After 22 hours,
the cells were stained with APC-conjugated tetramers (30 min,
37uC), followed by PE-conjugated anti-HA PE (GG8-IF3.3,
Miltenyi Biotec Inc.) (20 min, 20uC). The cells were washed and
fixed in 2% paraformaldehyde PBS. At least 200,000 events were
acquired using a FACSCalibur flow cytometer (BD Biosciences)
and the data was analyzed using FlowJo 8.8.6.
Mamu-KIR3DL05 genotyping
Genomic DNA was extracted from 1–2 million PBMC using the
DNAeasy kit (Qiagen, Valencia, CA), and 10 ng was used as
template in a 25 ml PCR reaction with forward and reverse
primers (GAGACCCATGAACTTAGGCTTC & GCAGTG-
GGTCACTGGGGA) for amplification of a 156 bp sequence in
exon 5 specific to Mamu-KIR3DL05. Primers specific for a
conserved 300 bp region of Mamu-DRB were included as an
internal control [48]. Cycling conditions included a denaturation
step at 96uC for 2 min followed by 30 cycles of denaturation (94uC
for 30 sec), annealing (63uC for 45 sec) and extension (72uC for
45 sec), and a final extension step at 72uC for 10 min. PCR
products were separated on a 1% agarose gel containing ethidium
bromide and visualized by UV transillumination.
NK cell suppression by specific MHC class I molecules
PBMC (1610
6 cells) were stimulated for 18 hours with 721.221
cells, or with 721.221 cells expressing rhesus macaque MHC class
I molecules, at a 5:1 ratio in the presence of anti-CD107a PE-Cy5
(clone H4A3, BD Pharmingen), Golgi-Stop and Golgi-plug (BD
Pharmingen). The cells were then stained with APC-conjugated
tetramers (30 min, 37uC), followed by anti-CD16-FITC, anti-
NKG2A-PE, anti-CD8a-Alexa 700 and CD3 APC-Cy7 (20 min,
20uC). The cells were then permeabilized and stained for 30 min
with anti-IFN-c-PE-CY7 (Clone 4S.B3, BD Pharmingen). Samples
were washed and fixed in 2% paraformaldehyde PBS. At least
200,000 lymphocyte events were collected using an LSRII flow
cytometer, and the data was analyzed using FlowJo 8.8.6.
Supporting Information
Figure S1 Mamu-KIR3DL07 does not bind to Mamu-
A1*00201. (A) An alignment comparing the predicted amino acid
sequences of the D0, D1 and D2 domains for six Mamu-KIR3DL07
alleles. Positions of amino acid identity with the consensus
sequence are indicated by a period. The shaded regions
correspond to loops predicted to contact surfaces of the peptide-
MHC class I complex. (B) Jurkat cells were electroporated with
constructs expressing HA-tagged allotypes of Mamu-KIR3DL07
and stained the following day with APC-conjugated Gag71-79 GY9
or Nef159-167 YY9. The cells were then stained with a PE-
conjugated antibody to the HA tag and analyzed by flow
cytometry. Tetramer versus HA staining is shown after gating
on the eGFP
+ cell population.
Found at: doi:10.1371/journal.ppat.1001316.s001 (0.85 MB
TIF)
Figure S2 The D1 domain of mmKIR3DL05x is identical to the
D1 domains encoded by Mamu-KIR3DS alleles. The amino acid
sequences of mmKIR3DL05x, Mamu-KIR3DS02*00402 and
mmKIR3DHa are shown aligned to Mamu-KIR3DL05*008.
Positions of amino acid identity are indicated with a period and
translational stop sites are indicated with an asterisk. The shaded
regions correspond to loops predicted to contact the peptide-MHC
class I complex.
Found at: doi:10.1371/journal.ppat.1001316.s002 (0.28 MB TIF)
Figure S3 Target cells expressing Mamu-A1*00201 suppress the
production of IFNc by tetramer-positive NK cells. PBMC from
two Mamu-A1*00201
+ and two Mamu-A1*00201
– macaques were
incubated overnight at a 5:1 effector to target cell ratio with
parental 721.221 cells, or with 721.221 cells expressing individual
rhesus macaque MHC class I molecules. Following stimulation,
the samples were stained with Gag71-79 GY9 tetramer, followed by
antibodies to CD3, CD8, CD16 and NKG2A. The samples were
then fixed, permeabilized and stained with an IFNc-specific
monoclonal antibody. After gating on CD3-NK2GA
+ lympho-
cytes, the frequency of tetramer-positive versus tetramer-negative
NK cells expressing IFNc was determined.
Found at: doi:10.1371/journal.ppat.1001316.s003 (0.34 MB TIF)
Table S1 Supplemental Table 1.
Found at: doi:10.1371/journal.ppat.1001316.s004 (0.04 MB
DOC)
Peptide-Selective Binding of KIR3DL to MHC Class I
PLoS Pathogens | www.plospathogens.org 11 March 2011 | Volume 7 | Issue 3 | e1001316Acknowledgments
We are grateful to Nancy Wilson and David Watkins at the University of
Wisconsin-Madison for providing the MHC class I tetramers used in this
study. We also thank Jackie Gillis and Michelle Connole at the New
England Primate Research Center for flow cytometry services.
Author Contributions
Conceived and designed the experiments: ADC DTE. Performed the
experiments: ADC WJN. Analyzed the data: ADC. Contributed reagents/
materials/analysis tools: BNB RKR GA MA RPJ MC DHO. Wrote the
paper: ADC DTE.
References
1. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23: 225–274.
2. Parham P (2005) MHC class I molecules and KIRs in human history, health and
survival. Nat Rev Immunol 5: 201–214.
3. Kim S, Sunwoo JB, Yang L, Choi T, Song Y-J, et al. (2008) HLA alleles
determine differences in human natural killer cell responsiveness and potency.
Proc Natl Acad Sci U S A 105: 3053–3058.
4. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL,
et al. (1997) Functionally and structurally distinct NK cell receptor repertoires in
the peripheral blood of two human donors. Immunity 7: 739–751.
5. Schwartz O, Marechal V, LeGall S, Lemonnier F, Heard J-M (1996)
Endocytosis of major histocompatibility complex class I molecules is induced
by the HIV-1 Nef protein. Nat Med 2: 338–342.
6. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, et al. (1999)
The selective downregulation of class I major histocompatibility complex
proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10:
661–671.
7. Fadda L, Borhis G, Ahmed P, Cheent K, Pageon SV, et al. (2010) Peptide
antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A
107: 10160–10165.
8. Ayers J, Cresswell P (1976) HLA-B specificities and w4, w6 specificities are on
the same polypeptide. Eur J Immunol 6: 794–799.
9. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P (1995) The Bw4
public epitope of HLA-B molecules confers reactivity with natural killer cell
clones that express NKB1, a putative HLA receptor. J Exp Med 181:
1133–1144.
10. Mandelboim O, Wilson SB, Vales-Gomez M, Reyburn HT, Strominger JL
(1997) Self and viral peptides can initiate lysis by autologous natural killer cells.
Proc Natl Acad Sci U S A 94: 5604–4609.
11. Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, et al. (2007)
Allele-specific and peptide-dependent interactions between KIR3DL1 and
HLA-A and HLA-B. J Immunol 178: 33–37.
12. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, et al. (2004)
Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific.
Eur J Immunol 34: 1673–1679.
13. Rajagopalan S, Long EO (1997) The direct binding of a p58 killer cell inhibitory
receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits
peptide selectivity. J Exp Med 185: 1523–1528.
14. Zappacosta F, Borrego F, Brooks AG, Parker KC, Coligan JE (1997) Peptides
isolated from HLA-Cw*0304 confer different degrees of protection from natural
killer cell-mediated lysis. Proc Natl Acad Sci U S A 94: 6313–6318.
15. Peruzzi M, Parker KC, Long EO, Malnati MS (1996) Peptide sequence
requirements for the recognition of HLA-B*2705 by specific natural killer cells.
J Immunol 157: 3350–3356.
16. Malnati MS, Peruzzi M, Parker KC, Biddison WE, Ciccone E, et al. (1995)
Peptide specificity in the recognition of MHC class I by natural killer cell clones.
Science 267: 1016–1018.
17. Fan QR, Long EO, Wiley DC (2001) Crystal structure of the human natural
killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol 2:
452–460.
18. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD (2000) Crystal
structure of an NK cell immunoglobulin-like receptor in complex with its class I
MHC. Nature 405: 537–543.
19. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, et al. (2007) Innate
partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 39:
733–740.
20. Martin MP, Gao X, Lee J-H, Nelson GW, Detels R, et al. (2002) Epistatic
interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat
Genet 31: 429–434.
21. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, et al. (2004) HLA and
NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science
305: 872–874.
22. Carrington M, Wang S, Martin MP, Gao X, Schiffman M, et al. (2005)
Hierarchy of resistance to cervical neoplasia mediated by combinations of killer
immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med
201: 1069–1075.
23. Chen C, Busson M, Rocha V, Appert M-L, Lepage V, et al. (2006) Activating
KIR genes are associated with CMV reactivation and survival after non-T-cell
depleted HLA-identical sibling bone marrow transplantation for malignant
disorders. Bone Marrow Transplant 38: 437–444.
24. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, et al. (2007)
Differential natural killer cell-mediated inhibition of HIV-1 replication based on
distinct KIR/HLA subtypes. J Exp Med 204: 3027–3036.
25. Letvin NL, Daniel MD, Sehgal PK, Desrosiers RC, Hunt RD, et al. (1985)
Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus
STLV-III. Science 230: 71–73.
26. Boyson JE, Schufflebotham C, Cadavid LF, Urvater JA, Knapp LA, et al. (1996)
The MHC class I genes of the rhesus monkey: Different evolutionary histories of
the MHC class I and II genes in primates. J Immunol 156: 4656–4665.
27. Adams EJ, Parham P (2001) Species-specific evolution of MHC class I genes in
the higher primates. Immunol Rev 183: 41–64.
28. Hershberger KL, Shyam R, Miura A, Letvin NL (2001) Diversity of the killer
cell Ig-like receptors of rhesus monkeys. J Immunol 166: 4380–4390.
29. Bimber BN, Moreland AJ, Wiseman RW, Hughes AL, O’Connor DH (2008)
Complete characterization of killer Ig-like receptor (KIR) haplotypes in
Mauritian cynomolgus macaques: Novel insights into nonhuman primate KIR
gene content and organization. J Immunol 181: 6301–6308.
30. Sambrook JG, Bashirova A, Palmer S, Sims S, Trowsdale J, et al. (2005) Single
haplotype analysis demonstrates rapid evolution of the killer immunoglobulin-
like receptor (KIR) loci in primates. Genome Res 15: 25–35.
31. Blokhuis JH, van der Wiel MK, Doxiadis GG, Bontrop RE (2010) The mosaic of
KIR haplotypes in rhesus macaques. Immunogenetics 62: 295–306.
32. Kruse PH, Rosner C, Walter L (2010) Characterization of rhesus macaque KIR
genotypes and haplotypes. Immunogenetics 62: 281–293.
33. Reeves RK, Gillis J, Wong FE, Yu Y, Connole M, et al. (2010) CD16- natural
killer cells: enrichment in mucosal and secondary lymphoid tissues and altered
function during chronic SIV infection. Blood 115: 4439–4446.
34. Loffredo JT, Sidney J, Wojewoda C, Dodds E, Reynolds MR, et al. (2004)
Idenification of seventeen new simian immunodeficiency virus-derived CD8+ T
cell epitopes restricted by the high frequency molecule, Mamu-A*02, and
potential escape from CTL recognition. J Immunol 173: 5064–5076.
35. Mingari MC, Schiavetti F, Ponte M, Vitale C, Maggi E, et al. (1996) Human
CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory
receptors represent oligoclonally or monoclonally expanded cell populations.
Proc Natl Acad Sci U S A 93: 12433–12438.
36. Anfossi N, Pasccal V, Vivier E, Ugolini S (2001) Biology of T memory type 1
cells. Immunol Rev 181: 269–278.
37. Sharma D, Bastard K, Guethlein LA, Norman PJ, Yawata N, et al. (2009)
Dimorphic motifs in D0 and D1 + D2 domains of killer cell Ig-like receptor
3DL1 combine to form receptors with high, moderate, and no avidity for the
complex of a peptide derived from HIV and HLA-A*2402. J Immunol 183:
4569–4582.
38. Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, et al. (2007) Cutting
edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes
a DAP12-associated receptor expressed on NK cells that triggers NK cell
activation. J Immunol 178: 647–651.
39. Khakoo SI, Geller R, Shin S, Jenkins JA, Parham P (2002) The D0 domain of
KIR3D acts as a major histocompatibility complex class I binding enhancer.
J Exp Med 196: 911–921.
40. Parham P (2006) Taking license with natural killer cell maturation and
repertoire development. Immunol Rev 214: 155–160.
41. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, et al. (2001)
Different NK cell surface phenotypes defined by the DX9 antibody are due to
KIR3DL1 gene polymorphism. J Immunol 166: 2992–3001.
42. Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, et al. (2002)
Genetic control of human NK cell repertoire. J Immunol 169: 239–247.
43. Yawata M, Yawata N, Draghi M, Little A-M, Parheniou F, et al. (2006) Roles
for HLA and KIR polymorphisms in natural killer cell repertoire selection and
modulation of effector function. J Exp Med 203: 633–645.
44. Alter G, Rihn S, Streeck H, Teigen N, Piechocka-Trocha A, et al. (2008)
Ligand-independent exhaustion of killer immunoglobulin-like receptor-positive
CD8+ T cells in human immunodefieciency virus type 1 infection. J Virol 82:
9668–9677.
45. Bonorino P, Leroy V, Dufeu-Duchesne T, Tongiani-Dashan S, Sturm N, et al.
(2007) Features and distribution of CD8 T cells with human leukocyte antigen
class I-specific receptor expression in chronic hepatitis C. Hepatology 46:
1375–1386.
46. Gumperz JE, Valiante NM, Parham P, Lanier LL, Tyan D (1996)
Heterogeneous phenotypes of expression of the NKB1 natural killer cell class
I receptor among individuals of different human histocompatibility leukocyte
antigens types appear genetically regulated, but not linked to major
histocompatibility complex haplotype. J Exp Med 183: 1817–1827.
47. Shimizu Y, Koller B, Geraghty D, Orr H, Shaw S, et al. (1986) Transfer of
cloned human class I major histocompatibility complex genes into HLA mutant
human lymphoblastoid cells. Mol Cell Biol 6: 1074–1087.
48. Kaizu M, Borchardt GJ, Glidden CE, Fisk DL, Loffredo JT, et al. (2007)
Molecular typing of major histocompatibility complex class I alleles in the Indian
Peptide-Selective Binding of KIR3DL to MHC Class I
PLoS Pathogens | www.plospathogens.org 12 March 2011 | Volume 7 | Issue 3 | e1001316rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics 59:
693–703.
49. Raulet DH, Vance RE, McMahon CW (2001) Regulation of the natural killer
cell receptor repertoire. Annu Rev Immunol 19: 291–330.
50. Pascal V, Stulberg MJ, Anderson SK (2006) Regulation of class I major
histocompatibility complex receptor expression in natural killer cells: one
promoter is not enough! Immunol Rev 214: 9–21.
51. Davies GE, Locke SM, Wright PW, Li H, Hanson RJ, et al. (2007) Identification
of bidirectional promoters in the human KIR genes. Genes Immun 8: 245–253.
52. Hoglund P, Brodin P (2010) Current perspectives of natural killer cell education
by MHC class I molecules. Nat Rev Immunol 10: 724–734.
53. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song Y-J, et al. (2005)
Licensing of natural killer cells by host major histocompatibility complex class I
molecules. Nature 436: 709–713.
54. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, et al. (2006) Human NK cell
education by inhibitory receptors for MHC class I. Immunity 25: 331–342.
55. Wiseman RW, Karl JA, Bimber BN, O’Leary CE, Lank SM, et al. (2009) Major
histocompatibility complex genotyping with massively parallel pyrosequencing.
Nat Med 15: 1322–1327.
56. Otting N, Heijmans CMC, Noort RC, de Groot NG, Doxiadis GG, et al. (2005)
Unparalleled complexity of the MHC class I region in rhesus macaques. Proc
Natl Acad Sci U S A 102: 1626–1631.
57. Mandelboim O, Reyburn HT, Valez-Gomez M, Pazmany L, Colonna M, et al.
(1996) Protection from lysis by natural killer cells of group 1 and 2 specificity is
mediated by residue 80 in human histocompatibility leukocyte antigen C alleles
and also occurs with empty major histocompatibility complex molecules. J Exp
Med 184: 913–922.
58. Rajalingam R, Parham P, Abi-Rached L (2004) Domain shuffling has been the
main mechanism forming new hominoid killer cell Ig-like receptors. J Immunol
172: 356–369.
59. DeGottardi MQ, Specht A, Metcalf B, Kaur A, Kirchhoff F, et al. (2008)
Selective downregulation of rhesus macaque and sooty mangabey major
histocompatibility complex class I molecules by nef alleles of simian
immunodeficiency virus and human immunodeficiency virus type 2. J Virol
82: 3139–3146.
60. Maria AD, Ferraris A, Guastella M, Pilia S, Cantoni C, et al. (1997) Expression
of HLA class I-specific inhibitory natural killer cell receptors in HIV-specific
cytolytic T lymphocytes: Impairment of specific cytolytic functions. Proc Natl
Acad Sci U S A 94: 10285–10288.
61. Bostik P, Kobkitjaroen J, Tang W, Villinger F, Pereira LE, et al. (2009)
Decreased NK cell frequency and function is associated with increased risk of
KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhesus
macaques with high viral loads. J Immunol 182: 3638–3649.
62. Anonymous (1996) The Institute of Laboratory Animal Resources, National
Research Council: Guide for the Care and Use of Laboratory Animals.
Washington, D.C.: National Academy Press. pp 86–123.
63. Robinson J, Mistry K, McWilliam H, Lopez R, Marsh SGE (2010) IPD-the
immuo polymorphism database. Nucleic Acids Res 38: D863–D869.
64. Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, et al. (1996) The natural
killer cell receptor specific for HLA-A allotypes: A novel member of the p58/p70
family of inhibitory receptors that is characterized by three immunoglobulin-like
domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med 184:
505–518.
Peptide-Selective Binding of KIR3DL to MHC Class I
PLoS Pathogens | www.plospathogens.org 13 March 2011 | Volume 7 | Issue 3 | e1001316